Neu-Ulm, Germany

Gertraud Koellner

This inventor holds 2 USPTO granted patents and 3 EPO patents. Top assignee: Ratiopharm Gmbh. Active years: 2015-2018.


 

Average Co-Inventor Count = 4.2

ph-index = 1


Company Filing History:


Years Active: 2015-2018

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Gertraud Koellner: Innovator in Pharmaceutical Chemistry

Introduction

Gertraud Koellner is a prominent inventor based in Neu-Ulm, Germany. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative drug formulations. With a total of 2 patents, her work focuses on improving the efficacy and delivery of medications.

Latest Patents

Koellner's latest patents include the development of Dolutegravir salts, specifically the Dolutegravir potassium salt and its solid-state forms. These innovations provide methods for making and interconverting these forms, which are crucial for treating individuals with HIV infection. Another notable patent involves desfesoterodine in the form of a tartaric acid salt, particularly in the polymorphic 'R form'. This invention also includes a process for its production and explores the microencapsulated form of desfesoterodine.

Career Highlights

Gertraud Koellner is currently associated with Ratiopharm GmbH, where she continues to advance her research in pharmaceutical formulations. Her work has been instrumental in developing new therapeutic options for patients in need.

Collaborations

Throughout her career, Koellner has collaborated with esteemed colleagues such as Wolfgang Albrecht and Ludovic Coutable. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Gertraud Koellner's contributions to pharmaceutical chemistry exemplify her dedication to improving medical treatments. Her innovative patents and collaborative efforts continue to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…